EMEA (Europe, Middle East and Africa) Adrenoleukodystrophy Drugs Market Report 2019

REPORT ID 3383

EMEA (Europe, Middle East and Africa) Adrenoleukodystrophy Drugs Market Report 2019

Publish Date

2019

Pages

109

Format

Electronic (PDF)

Full report description

In this report, the EMEA Adrenoleukodystrophy Drugs market is valued at USD   XX million in 2019 and is expected to reach USD  XX million by the end of 2025, growing at a CAGR of  XX% between 2019 and 2025.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Adrenoleukodystrophy Drugs for these regions, from   2019 to 2025 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Adrenoleukodystrophy Drugs market competition by top manufacturers/players, with Adrenoleukodystrophy Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Applied Genetic Technologies Corp
    Bluebird Bio Inc
    MedDay SA
    Minoryx Therapeutics sl
    Pfizer Inc
    ReceptoPharm Inc
    SOM Biotech SL
    Viking Therapeutics Inc

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Biotin
    DRX-065
    DUOC-01
    Lenti-D
    MIN-102
    OP-101
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Children
    Adult

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of contents

Table of Contents

EMEA (Europe, Middle East and Africa) Adrenoleukodystrophy Drugs Market  Report 2019
1 Adrenoleukodystrophy Drugs Overview
    1.1 Product Overview and Scope of Adrenoleukodystrophy Drugs
    1.2 Classification of Adrenoleukodystrophy Drugs
        1.2.1 EMEA Adrenoleukodystrophy Drugs Market Size (Sales) Comparison by Type ( 2014-2024)
        1.2.2 EMEA Adrenoleukodystrophy Drugs Market Size (Sales) Market Share by Type (Product Category)  in 2018
        1.2.3 Biotin
        1.2.4 DRX-065
        1.2.5 DUOC-01
        1.2.6 Lenti-D
        1.2.7 MIN-102
        1.2.8 OP-101
        1.2.9 Others
    1.3 EMEA Adrenoleukodystrophy Drugs Market by Application/End Users
        1.3.1 EMEA Adrenoleukodystrophy Drugs Sales (Volume) and Market Share Comparison by Application ( 2014-2024
        1.3.2 Children
        1.3.3 Adult
    1.4 EMEA Adrenoleukodystrophy Drugs Market by Region
        1.4.1 EMEA Adrenoleukodystrophy Drugs Market Size (Value) Comparison by Region ( 2014-2024)
        1.4.2 Europe Status and Prospect ( 2014-2024)
        1.4.3 Middle East Status and Prospect ( 2014-2024)
        1.4.4 Africa Status and Prospect ( 2014-2024)
    1.5 EMEA Market Size (Value and Volume) of Adrenoleukodystrophy Drugs ( 2014-2024)
        1.5.1 EMEA Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2024)
        1.5.2 EMEA Adrenoleukodystrophy Drugs Revenue and Growth Rate ( 2014-2024)

2 EMEA Adrenoleukodystrophy Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Adrenoleukodystrophy Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Adrenoleukodystrophy Drugs Sales Volume and Market Share of Major Players ( 2014-2019)
        2.1.2 EMEA Adrenoleukodystrophy Drugs Revenue and Share by Players ( 2014-2019)
        2.1.3 EMEA Adrenoleukodystrophy Drugs Sale Price by Players ( 2014-2019)
    2.2 EMEA Adrenoleukodystrophy Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Adrenoleukodystrophy Drugs Sales and Market Share by Type ( 2014-2019)
        2.2.2 EMEA Adrenoleukodystrophy Drugs Revenue and Market Share by Type ( 2014-2019)
        2.2.3 EMEA Adrenoleukodystrophy Drugs Sale Price by Type ( 2014-2019)
    2.3 EMEA Adrenoleukodystrophy Drugs (Volume) by Application
    2.4 EMEA Adrenoleukodystrophy Drugs (Volume and Value) by Region
        2.4.1 EMEA Adrenoleukodystrophy Drugs Sales and Market Share by Region ( 2014-2019)
        2.4.2 EMEA Adrenoleukodystrophy Drugs Revenue and Market Share by Region ( 2014-2019)
        2.4.3 EMEA Adrenoleukodystrophy Drugs Sales Price by Region ( 2014-2019)

3 Europe Adrenoleukodystrophy Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Adrenoleukodystrophy Drugs Sales and Value ( 2014-2019)
        3.1.1 Europe Adrenoleukodystrophy Drugs Sales Volume and Growth Rate ( 2014-2019)
        3.1.2 Europe Adrenoleukodystrophy Drugs Revenue and Growth Rate ( 2014-2019)
    3.2 Europe Adrenoleukodystrophy Drugs Sales and Market Share by Type
    3.3 Europe Adrenoleukodystrophy Drugs Sales and Market Share by Application
    3.4 Europe Adrenoleukodystrophy Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Adrenoleukodystrophy Drugs Sales Volume by Countries ( 2014-2019)
        3.4.2 Europe Adrenoleukodystrophy Drugs Revenue by Countries ( 2014-2019)
        3.4.3 Germany Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)
        3.4.4 France Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)
        3.4.5 UK Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)
        3.4.6 Russia Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)
        3.4.7 Italy Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)
        3.4.8 Benelux Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)

4 Middle East Adrenoleukodystrophy Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Adrenoleukodystrophy Drugs Sales and Value ( 2014-2019)
        4.1.1 Middle East Adrenoleukodystrophy Drugs Sales Volume and Growth Rate ( 2014-2019)
        4.1.2 Middle East Adrenoleukodystrophy Drugs Revenue and Growth Rate ( 2014-2019)
    4.2 Middle East Adrenoleukodystrophy Drugs Sales and Market Share by Type
    4.3 Middle East Adrenoleukodystrophy Drugs Sales and Market Share by Application
    4.4 Middle East Adrenoleukodystrophy Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Adrenoleukodystrophy Drugs Sales Volume by Countries ( 2014-2019)
        4.4.2 Middle East Adrenoleukodystrophy Drugs Revenue by Countries ( 2014-2019)
        4.4.3 Saudi Arabia Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)
        4.4.4 Israel Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)
        4.4.5 UAE Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)
        4.4.6 Iran Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)

5 Africa Adrenoleukodystrophy Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Adrenoleukodystrophy Drugs Sales and Value ( 2014-2019)
        5.1.1 Africa Adrenoleukodystrophy Drugs Sales Volume and Growth Rate ( 2014-2019)
        5.1.2 Africa Adrenoleukodystrophy Drugs Revenue and Growth Rate ( 2014-2019)
    5.2 Africa Adrenoleukodystrophy Drugs Sales and Market Share by Type
    5.3 Africa Adrenoleukodystrophy Drugs Sales and Market Share by Application
    5.4 Africa Adrenoleukodystrophy Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Adrenoleukodystrophy Drugs Sales Volume by Countries ( 2014-2019)
        5.4.2 Africa Adrenoleukodystrophy Drugs Revenue by Countries ( 2014-2019)
        5.4.3 South Africa Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)
        5.4.4 Nigeria Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)
        5.4.5 Egypt Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)
        5.4.6 Algeria Adrenoleukodystrophy Drugs Sales and Growth Rate ( 2014-2019)

6 EMEA Adrenoleukodystrophy Drugs Manufacturers/Players Profiles and Sales Data
    6.1 Applied Genetic Technologies Corp
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Adrenoleukodystrophy Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Applied Genetic Technologies Corp Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.1.4 Main Business/Business Overview
    6.2 Bluebird Bio Inc
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Adrenoleukodystrophy Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.2.4 Main Business/Business Overview
    6.3 MedDay SA
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Adrenoleukodystrophy Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 MedDay SA Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.3.4 Main Business/Business Overview
    6.4 Minoryx Therapeutics sl
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Adrenoleukodystrophy Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Minoryx Therapeutics sl Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.4.4 Main Business/Business Overview
    6.5 Pfizer Inc
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Adrenoleukodystrophy Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Pfizer Inc Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.5.4 Main Business/Business Overview
    6.6 ReceptoPharm Inc
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Adrenoleukodystrophy Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 ReceptoPharm Inc Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.6.4 Main Business/Business Overview
    6.7 SOM Biotech SL
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Adrenoleukodystrophy Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 SOM Biotech SL Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.7.4 Main Business/Business Overview
    6.8 Viking Therapeutics Inc
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Adrenoleukodystrophy Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Viking Therapeutics Inc Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.8.4 Main Business/Business Overview

7 Adrenoleukodystrophy Drugs Manufacturing Cost Analysis
    7.1 Adrenoleukodystrophy Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Adrenoleukodystrophy Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Adrenoleukodystrophy Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Adrenoleukodystrophy Drugs Major Manufacturers  in 2018
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Adrenoleukodystrophy Drugs Market Forecast ( 2019-2025)
    11.1 EMEA Adrenoleukodystrophy Drugs Sales, Revenue and Price Forecast ( 2019-2025)
        11.1.1 EMEA Adrenoleukodystrophy Drugs Sales and Growth Rate Forecast ( 2019-2025)
        11.1.2 EMEA Adrenoleukodystrophy Drugs Revenue and Growth Rate Forecast ( 2019-2025)
        11.1.3 EMEA Adrenoleukodystrophy Drugs Price and Trend Forecast ( 2019-2025)
    11.2 EMEA Adrenoleukodystrophy Drugs Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.3 Europe Adrenoleukodystrophy Drugs Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.4 Middle Eastt Adrenoleukodystrophy Drugs Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.5 Africa Adrenoleukodystrophy Drugs Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.6 EMEA Adrenoleukodystrophy Drugs Sales Forecast by Type ( 2019-2025)
    11.7 EMEA Adrenoleukodystrophy Drugs Sales Forecast by Application ( 2019-2025)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer